MSL Pharma

MSL Pharma, whose legal name appears to be Met Syn Lysine, is an Israel-based early-stage biotech/pharma company focused on peptide and peptidomimetic therapeutics and drug-delivery technologies. The company describes itself as holding exclusive academic licenses and operating a lean virtual-development model that outsources laboratory and development work to universities and CRO partners. Its disclosed programs center on metabolic disease, especially obesity, metabolic syndrome, and type 2 diabetes, and external databases also indicate early clinical-stage assets named Backtide E and Backtide D. Beyond lead therapeutic programs, the company highlights platform capabilities in cyclic peptides, tumor-targeting peptides, and coated liposomes for oral delivery of peptides and other macromolecules. Overall, MSL Pharma appears to be a small, private Israeli biotech developing platform-enabled peptide medicines with applications in metabolic disease and oncology.